192 related articles for article (PubMed ID: 9306432)
1. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
[TBL] [Abstract][Full Text] [Related]
2. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: mechanistic studies. II.
Papadopoulou MV; Rosenzweig HS; Ji M; Khan SH; Bloomer WD
Oncol Res; 1998; 10(3):163-73. PubMed ID: 9700727
[TBL] [Abstract][Full Text] [Related]
3. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
[TBL] [Abstract][Full Text] [Related]
4. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
Papadopoulou MV; Ji M; Bloomer WD
In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811
[TBL] [Abstract][Full Text] [Related]
5. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
Papadopoulou MV; Bloomer WD
Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
[TBL] [Abstract][Full Text] [Related]
8. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1.
Papadopoulou MV; Rosenzweig HS; Doddi M; Bloomer WD
Oncol Res; 1994; 6(9):439-48. PubMed ID: 7703530
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
Papadopoulou MV; Ji X; Bloomer WD
Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
[TBL] [Abstract][Full Text] [Related]
10. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
11. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
12. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Pouremad R; Rao MK; Ji M; Bloomer WD
In Vivo; 2001; 15(5):365-71. PubMed ID: 11695231
[TBL] [Abstract][Full Text] [Related]
14. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Ji M; Bloomer WD
Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
[TBL] [Abstract][Full Text] [Related]
15. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
16. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
Papadopoulou MV; Ji X; Bloomer WD
J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
[TBL] [Abstract][Full Text] [Related]
18. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitizing and toxic properties of quinoline and nitroquinoline complexes of platinum [PtCl2(NH3)quinoline].
Skov KA; Adomat H; Doedee M; Farrell N
Anticancer Drug Des; 1994 Apr; 9(2):103-17. PubMed ID: 8166927
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
Shyam K; Penketh PG; Shapiro M; Belcourt MF; Loomis RH; Rockwell S; Sartorelli AC
J Med Chem; 1999 Mar; 42(5):941-6. PubMed ID: 10072691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
